RE:RE:RE:Monday N.R- The following article: Telesta Therapeutics: Near-Term Catalyst Could Provide Multi-Bagger Returns
Valuation summary (all share prices in US dollars)
• Fair valuation today: $300 million. Shareprice: $1.04.
• Fair valuation following positive advisory committee recommendation: $600 million. Shareprice: $2.08.
• Fair valuation following 2nd Phase 3 trial recommendation: $150 million. Shareprice: $.52.
• For valuation following 2nd phase 3 trial recommendation with concurrent FDA approved drug sales: valuation $400 million. Shareprice: $1.38.
• Fair valuation following FDA approval: $1 billion. Shareprice: $3.47.
• Fair valuation long-term following FDA approval: $3 billion to $4.5 billion. Shareprice: $10.41 to $15.62.